Source comparison
Best BPC-157 Dosage for Tendon Healing: Protocol Comparison
| Protocol | Daily Dose | Administration Route | Duration | Clinical Outcome | Research Basis | Professional Assessment ||—|—|—|—|—|—|| Standard Therapeutic | 250–350 mcg | Subcutaneous (near injury site) | 4–6 weeks | 40–60% improvement in tendon tensile stre
This comparison does not assign a generated winner or score.
- | Protocol | Daily Dose | Administration Route | Duration | Clinical Outcome | Research Basis | Professional Assessment ||—|—|—|—|—|—|| Standard Therapeutic | 250–350 mcg | Subcutaneous (near injury site) | 4–6 weeks | 40–60% improvement in tendon tensile strength vs baseline | University of Zagreb studies (2010, 2014) | Gold standard for single-site tendon repair. Highest local bioavailability || Conservative Start | 200 mcg | Subcutaneous (near injury site) | 6–8 weeks | 30–45% improvement in tensile strength. Slower onset | Derived from minimum effective dose in animal models | Appropriate for first-time users or mild tendinopathy. Extends timeline || High-Dose Protocol | 500 mcg | Subcutaneous (near injury site) | 4 weeks | No additional benefit vs 250–350 mcg; higher injection site reaction rate | Dose-response ceiling identified in rat models | Not recommended. Cost increase without efficacy gain || Systemic Multi-Site | 300 mcg | Intramuscular (deltoid or vastus lateralis) | 4–6